A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side effect of Novo Nordisk's popular treatments Ozempic and Wegovy, it said on ...

“The legal tangle over Novo Nordisk’s weightloss and diabetes drug semaglutide will be a “test case” of sorts, say intellectual property (IP) experts, as more Indian drugmakers wait in the ...

A legal tangle hovers over Novo Nordisk’s diabetes and weightloss drug semaglutide, just weeks ahead of the possible launch of its injectible version Wegovy in India. Semaglutide is the active ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy. Novo Nordisk has announced ...

With a U.S. Food and Drug Administration ban on copycat semaglutide drugs now in effect, Novo Nordisk is launching a series of initiatives to improve access to authentic versions of its ...

Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn ...

senior vice president and head of Chief Medical Office at Novo Nordisk. “Our broad and robust semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and ...

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. ...

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized ...